Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Covaxin effective against the Brazilian variant: ICMR-NIV study

Covaxin effective against the Brazilian variant: ICMR-NIV study



In a new study, researchers at the Indian Council of Medical Research-National Institute of Virology have found that Covaxin is effective against the Brazilian variant (B.1.128.2).

This comes close to the heels of their recent study, which had also suggested that Covaxin was effective against both the British variant and the Indian (double mutant) variant B.1.617.

India is currently using two Covid 19 vaccines, Covaxin by Bharat Biotech and Covishield by the Serum Institute of India, to vaccinate people across the country.

There is evidence that the country’s original Covid-19 jab Covaxin is proving to be effective against some variants.

Dr Anthony Fauci, Chief Adviser to US President Joe Biden on the Covid Pandemic, cited recent Phase 3 clinical trials of Covaxin by the ICMR, which claimed that the vaccine neutralizes multiple variants of SARS-CoV-2 and effectively neutralizes the dual mutant strain (B1

617) also.

In this new study, published in bioRxiv pre-print on April 30, researchers have shown that Covaxin is effective against the Brazilian variant (B.1.1.28.2).

A new study shows that the two-dose Covaxin regimen significantly boosted IgG (antibody) titers and neutralized the effectiveness against the Brazil variant and the D614G variant compared to that seen with natural infection.

Led by NIV researchers Gajanan Sapkal, Pragya Yadav, Priya Abraham and others, they said it was a robust neutralization of B1 and B.1.1.28.2 variants among vaccine recipients.

Researchers determined the IgG immune response and neutralization activity of the 19 convalescent sera samples obtained from the recovered cases of COVID-19 and confirmed for UK (B.1.1.7), South Africa (B.1.351) and Brazil (B.1.1. 28.2) variants (15-113 days after positive test) and from 42 participants immunized with an inactivated Covid-19 vaccine, BBV 152 (Covaxin) as part of a Phase II clinical trial (two months after the second dose).

The response was observed with recovered cases, but the study found a better response from samples of Covaxin vaccine recipients, researchers said.

India has reported cases infected with the SARS-CoV-2 UK variant (B.1.1.7). Recently, the South African variant (B.1.351) and Brazil variant P2 genus (B.1.1.28.2) have also been detected in international travelers traveling to India from abroad.

The effect of the emergence of these new variants on the effect of the currently available COVID-19 vaccines or the neutralizing ability of sera in individuals naturally infected with the previously circulating strains is currently being investigated.

Although some of the vaccines appear to be effective against the British variant, it has been shown that the effect against the South African variant is less effective.

According to a recent NCDC report, among 15,000 sequenced samples, 11 percent included these variants of concern

By the first week of April, the number of cases of COVID virus in the UK, South Africa and Brazil had reached 948.


Source link